CompletedPhase 2NCT01967576
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Studying Hereditary pheochromocytoma-paraganglioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Andrea B Apolo, M.D.National Cancer Institute (NCI)
- Intervention
- Axitinib (AG-013736)(drug)
- Enrollment
- 14 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2013 – 2020
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01967576 on ClinicalTrials.govOther trials for Hereditary pheochromocytoma-paraganglioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06479811[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersNational Cancer Institute (NCI)
- RECRUITINGNANCT06377033Using the EHR to Advance Genomic Medicine Across a Diverse Health SystemUniversity of Pennsylvania
- RECRUITINGNCT06444607Hereditary Pheochromocytoma Assessment of Tumour ImmunologiesRadboud University Medical Center
- RECRUITINGPHASE4NCT05702944The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive PheochromocytomaSeoul National University Hospital
- ACTIVE NOT RECRUITINGNCT05233878Prognostic's Factors of Head and Neck Paragangliomas EvolutionHospices Civils de Lyon
- ACTIVE NOT RECRUITINGPHASE2NCT05142241Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 TrialNational Cancer Institute (NCI)
- RECRUITINGNANCT03344016Multicenter Pheochromocytoma and Paraganglioma EvaluationFelix Beuschlein
- RECRUITINGNANCT02402244Project: Every Child for Younger Patients With CancerChildren's Oncology Group
See all trials for Hereditary pheochromocytoma-paraganglioma →